Patient's Whole Process Follow-up Management(HOPE-1)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1268 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-22

Study Completion Date

2030-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer

NCT03413956

Non Small Cell Lung Cancer

COMPLETED

Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer

NCT03505515

Lung Cancer Non-small Cell Lung Cancer NSCLC Small Cell Lung Cancer SCLC

COMPLETED

Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation

NCT04137718

Chinese Non-Small Cell Lung Cancer

UNKNOWN

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

NCT06183762

Advanced Lung Cancer

RECRUITING

Survival Outcomes of Lung Cancer

NCT03647098

Lung Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Now, the treatment of NSCLC is diversiform, such as radiation and chemotherapy, targeted therapy, immune therapy, the treatment goal is to reduce symptoms, improve quality of life, prolong life. But as a result of the disease itself has the high risk of metastasis and recurrence. The treatment is often accompanied by a series of complications, if the patients don't get medical assistance in time, it will lead high risk to physical and mental health of patients. In China, the intermittent period of domestic treatment is mainly family recuperation, but due to the lack of medical knowledge or self-management and self-restraint ability of patients, they may forget to take medicine, stop medication without permission due to side effects and other behaviors that do not follow the doctor's advice, the poorly patients' compliance will lead to a significant reduction in the treatment effect. NSCLC are often accompanied by anxiety, fear, insomnia and other symptoms, causing a huge psychological burden on patients and their families, affecting the quality of life. Whole process follow-up in tumor therapy plays an important role , it is the crucial link between medical, nursing, and patients. Patients' whole process follow-up and management is an important part of cancer disease management.

It is helpful to relieve the patients and their families of the bad psychology, reduce the symptoms of patients, improve the patient's compliance behavior, relieve the psychological anxiety of patients, make it actively cooperate with the treatment, reduce complications, improve the quality of life of patients, so as to prolong the life cycle.

Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Locally Advanced Non-Small Cell Lung Cancer Metastatic NSCLC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Platform follow-up cohort

This cohort will be managed and follow-up by patients' whole process follow-up platform. The patients can report the symptoms, get the reminder of the hospital visit, get the reminder of medicine taking, get the information of patients education.

Patients' whole process follow-up and management platform

Intervention Type OTHER

Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.

Routine follow-up cohort

This cohort will be managed and follow-up by the investigators or nurses. This cohort will take the routine follow-up and management way by the hospital.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patients' whole process follow-up and management platform

Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Fully understand the research and voluntarily sign the informed consent form (ICF)
2. Male or female subjects who are over 18 years old (inclusive) at the time of signing the informed consent form.
3. The subject is diagnosed pathologically or cytologically with non-small cell lung cancer(NSCLC).
4. According to the 8th edition of the American Joint Committee on Cancer \[AJCC\], it is classified as stage IIB, stage III, stage IV NSCLC.
5. Not suitable for radical treatment or refuse surgery.
6. The life expectancy is not less than 3 months.
7. Be able to use a smartphone.

Exclusion Criteria

1. Patients with mental illness.
2. Presence of any other malignant tumor.
3. Patients who are expected to undergo radical surgery.
4. Currently participating in clinical trials.
5. Subjects who judged by the investigator to be unsuitable to participate in the trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No